PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32820157-8	2020	Further, we found that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) reduced obviously the expression of IRX4 and NANOG by inhibiting the activation of TGF-beta1/Smad3 signaling pathway; moreover, combination of 1,25(OH)2D3 and gefitinib decreased cell viability and proliferation or tumor progression and the expression of IRX4 and NANOG compared with single treatment alone both in PC-9/GR cells and in a PC-9/GR xenograft tumor model.	Gefitinib	221-230	Nanog homeobox	Homo sapiens	107-112	
34145929-11	2021	Moreover, overexpression of MSI2 or Nanog conferred resistance to osimertinib or gefitinib in parental cells.	Gefitinib	81-90	Nanog homeobox	Homo sapiens	36-41	
32820157-5	2020	Combination of knocking-down IRX4 with gefitinib increased cell apoptosis and decreased cell viability and the expression of p-EGFR and NANOG in PC-9/GR cells.	Gefitinib	39-48	Nanog homeobox	Homo sapiens	136-141	
32820157-7	2020	Knockdown of NANOG inhibited the expression of CD133 and restored gefitinib cytotoxicity, and NANOG overexpression-induced cancer stem-like properties and gefitinib resistance could be obviously reversed by knocking-down IRX4.	Gefitinib	66-75	Nanog homeobox	Homo sapiens	13-18	
32820157-10	2020	Combination therapy of gefitinib and 1,25(OH)2D3 by targeting IRX4 and NANOG, could provide a promising strategy to improve gefitinib cytotoxicity.	Gefitinib	23-32	Nanog homeobox	Homo sapiens	71-76	
32820157-10	2020	Combination therapy of gefitinib and 1,25(OH)2D3 by targeting IRX4 and NANOG, could provide a promising strategy to improve gefitinib cytotoxicity.	Gefitinib	124-133	Nanog homeobox	Homo sapiens	71-76	
32428834-4	2020	Here, we found a significant elevated expression of both Oct4 and Nanog in gefitinib-resistant NSCLC cells, which displayed multi-drug resistance (MDR) properties and exhibited EMT phenotype.	Gefitinib	75-84	Nanog homeobox	Homo sapiens	66-71